#Market News January 8, 2018 / 4:53 PM / Updated 38 minutes ago BRIEF-Ironwood Pharmaceuticals Sees U.S. Net Sales Of Linzess Of About $700 Million‍​ For FY Ended Dec 31, 2017 Reuters Staff 1 Min Read 
Jan 8 (Reuters) - Ironwood Pharmaceuticals Inc: 
* IRONWOOD PHARMACEUTICALS INC - EXPECTED U.S. NET SALES OF LINZESS (LINACLOTIDE) OF ABOUT $700 MILLION‍​ FOR FY ENDED DEC 31, 2017 
* IRONWOOD PHARMACEUTICALS - ‍EXPECTED IRONWOOD REVENUE FROM LINACLOTIDE API SALES TO ASTELLAS OF MORE THAN $100 MILLION FROM JAN 1, 2017 TO DEC 31, 2019​ 
* IRONWOOD PHARMACEUTICALS- EXPECTED REVENUE CAGR FROM THE LINZESS U.S. COLLABORATION WITH ALLERGAN OF ABOUT 75% FOR YEAR ENDED DEC 31, 2014 TO 2017 
* IRONWOOD PHARMACEUTICALS- EXPECTED LINZESS U.S. NET SALES CAGR OF GREATER THAN 30% FOR YEAR ENDED DEC 31, 2014 TO YEAR ENDED DECEMBER 31, 2017 Source text : ( bit.ly/2CQ3Ise ) Further company coverage: